Clinical Scorecard: Investigating Viral Infections and Their Impact on the Blood-Brain Barrier: Insights from Molecular Research and Therapeutic Approaches
At a Glance
Category
Detail
Condition
Blood-brain barrier (BBB) dysfunction due to viral infections
Key Mechanisms
Direct neurotropism, Trojan horse mechanisms, systemic infection and inflammation causing BBB permeability and immune-mediated damage
Target Population
Patients with viral infections affecting the central nervous system (e.g., HSV-1, varicella zoster virus, HIV, Japanese encephalitis virus, SARS-CoV-2)
Care Setting
Neurology and infectious disease clinical settings, including inpatient and outpatient care for viral encephalitis and related neurologic complications
Key Highlights
The BBB is maintained by brain endothelial cells, pericytes, and astrocytes forming the neurovascular unit (NVU), critical for CNS protection.
Viral infections can disrupt BBB integrity leading to severe neurologic complications such as encephalitis, meningitis, and microcephaly.
Clinical assessment of BBB integrity includes CSF/serum albumin quotient, dynamic contrast-enhanced MRI, and blood biomarkers like GFAP, S100B, NfL, and tau.
Guideline-Based Recommendations
Diagnosis
Use CSF/serum albumin quotient to assess BBB permeability, acknowledging limitations due to microglial albumin production.
Employ dynamic contrast-enhanced MRI with gadolinium contrast for minimally invasive and accurate BBB permeability measurement.
Measure blood biomarkers (GFAP, S100B, NfL, tau) using ultrasensitive assays to detect NVU damage.
Management
Current therapies primarily target viral replication; neuroprotective strategies to preserve BBB integrity are under investigation.
Address immune-mediated damage to reduce cellular injury and cerebral edema in viral CNS infections.
Monitoring & Follow-up
Monitor BBB integrity using serial imaging and biomarker levels to evaluate disease progression and therapeutic response.
Risks
BBB breakdown increases risk of severe neurologic morbidity and mortality including encephalitis, meningitis, and microcephaly.
Patient & Prescribing Data
Patients with CNS viral infections such as HSV-1 encephalitis
Therapies focus on antiviral agents; limited options exist specifically targeting BBB repair or protection.
Clinical Best Practices
Integrate biomarker and imaging data for comprehensive assessment of BBB integrity in viral CNS infections.
Consider the distinct physiology of blood-brain and blood-CSF barriers when interpreting diagnostic tests.
Recognize the contribution of both direct viral effects and immune-mediated mechanisms in BBB disruption.
by Sarah A Boardman, Claire Hetherington, Thomas Hughes, Callum Cook, Ian Galea, Orla Hilton, Tom Solomon, Andrew D Luster, Stuart Allan, Evelyn Kurt-Jones, Joe Forth, Adjanie Patabendige, Franklyn N Egbe, Cordelia Dunai, Benedict D Michael
